摘要
目的 :观察高脂血症患者调脂治疗前后 ,血浆C -反应蛋白 (CRP)及维蛋白原 (FIB)的水平变化。方法 :选择住院的高脂血症患者 6 0例 ,随机分为两组 ,其中普罗布考组 (n =32 )给予普罗布考 ,普伐他汀组 (n =2 8) ,给予普伐他汀 10 ,疗程均为 4w。治疗前后分别测血脂、CRP和FIB。结果 :(1)普罗布考和普伐他汀均可显著降低总胆固醇 (TC)和低密度脂蛋白胆固醇 (LDL -C) ,(2 )普罗布考对FIB和CRP无显著影响 ;而普伐他汀显著升高FIB ,从 (3 2 5± 0 89) g/L升至 (3 87± 0 75 )g/L (P <0 0 5 ) ,对CRP无明显影响。 (3)普伐他汀组FIB的升高与胆固醇的降低无相关性。结论 :调脂治疗不能同时降低CRP和FIB 。
Objective:To observe the plasma levels of C-reactive protein(CRP) and fibrinogen(FIB) in patients with hyperlipidemia before and after the lipid lowering therapy.Methods:60 patients with hyperlipidmia were randomized devided into probucol group( n =32) and pravastatin group( n =28).The probucol group was given probucol,and the pravastatin group was given pravastatin.The plasma levels of CRP and FIB were measured before and after 4 weeks therapy.Results:After 4 weeks treatment with probucol and pravastatin,the levels of total cholesterol(TC) and low-density cholesterol(LDL-c) were reduced markedly,the level of CRP had no significantly changed,but FIB and significantly increased in pravastatin group from(3 25±0 89) g/L to (3 87±0 75)g/L( P <0 05).There was no correlation between the increased levels of FIB and the decreased of TC.Conclusion:The lipid lowering therapy cann't lower CRP and FIB,the hyperlipidemia should be versatilely treated.
出处
《武警医学院学报》
CAS
2003年第3期177-179,共3页
Acta Academiae Medicinae CPAPF
